Merck Reports Data from the P-III (STRIDE-10) Trial of V116 Pneumococcal Conjugate Vaccine for Adults
Shots:
- The P-III (STRIDE-10) trial assessed the immunogenicity, tolerability and safety of V116 vs PPSV23 in adults (n=1,484, 50yrs. & above) not receiving pneumococcal vaccine before
- The study depicted non-inferior immune responses with V116 for the 12 shared serotypes with PPSV23, superior immune responses for the 9 serotypes unique to V116 & superior immune responses for 8/9 serotypes unique to V116 as evaluated by the proportions of patients with ≥4-fold rise
- Furthermore, V116’s review by the US FDA & the EMA is currently underway. The drug also received the US FDA’s priority review with the decision anticipated in Jun 2024
Ref: Merck | Image: Merck
Related News:- Merck Highlights Results from Various P-III Trials of V116 Vaccine for Pneumococcal Diseases at ISPPD-13 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
